Optigenex Inc. Renews Its Agreement With RFI Ingredients for Marketing and Sale of AC-11(R) in Retail and Direct to

NEW YORK, NY, Feb 18 (MARKET WIRE) --
Optigenex Inc. (PINKSHEETS: OPGX) announced today the signing with RFI,
LLC of a new, non-exclusive Supply and Trademark License Agreement for
the territory of North America. The new agreement renews the parties'
several year-long business relationship and extends continuing rights to
RFI to manufacture and market dietary supplement products containing
AC-11(R) (formerly known as C-Med-100(R)). Both parties anticipate that
this timely recommitment will reap mutual benefits, as the growing body
of AC-11(R) scientific validation recently has opened several new doors
for capitalizing on Optigenex's patented technology, especially in the
novel field of advanced, oral-based sun care products.

Jeff Wuagneux, President and CEO of RFI, stated, "We are very excited to
continue our work with the management of Optigenex to promote the AC-11(R)
product into the natural healthcare industry. Over the past several years
we have come to value the science behind AC-11(R), and Optigenex's
commitment to furthering the clinical validation of the technology. RFI is
dedicated to promoting and marketing science based products, and we feel
confident that AC-11(R) will have a great impact as a key strategic
component in both the oral-based sun care market, as well as the DNA
repair and antioxidant categories."

Daniel Zwiren, President and CEO of Optigenex, added, "We are pleased with
the opportunity to renew our excellent relationship with RFI. Jeff and his
team have demonstrated an impressive understanding and command of the
market, as well as a strong loyalty to AC-11(R) technology over the past
two years in the direct to physician's channel. The signing of this
expanded agreement was an easy decision for us, because RFI in an
impressive fashion has grown its business vertically from wholesale
ingredient supplier to a finished product, direct to consumer marketing
company. We are confident that RFI is positioned to market AC-11(R) on a
large scale to health conscious, educated consumers in North America."

About RFI, LLC:

RFI, LLC is a U.S. based (New York, Colorado) Life Science Development and
Commercialization Company offering a pipeline of novel compounds and
proprietary science-based nutritional bioactive formulas for the food,
dietary supplement, practitioner, direct selling and direct to consumer
marketing channels.

About Optigenex Inc.:

Optigenex Inc. is a formulator, distributor and provider of proprietary
next generation skin care technology, dietary supplements and bulk
ingredient featuring AC-11(R) as its core product. AC-11(R) (formerly
known as C-MED-100(R)) is a patented, bioactive and water soluble rain
forest compound derived from the medicinal herb Uncaria tomentosa. For
more information about Optigenex please visit our website:
www.optigenex.com

*The statements made in this press release have not been evaluated by the
Food and Drug Administration (FDA). The products mentioned herein are not
intended to diagnose, treat, cure or prevent any disease.

Dan Zwiren
President and CEO
Optigenex Inc.
dzwiren@optigenex.com
201 355 2098

Copyright 2010, Market Wire, All rights reserved.

-0-